3 Drug Stocks Hitting 52-Week Highs: Are They Buys?
October has often been a scary month for stocks. That isn't the case so far this year, though. And it's especially not true for three drug stocks.
Biogen (NASDAQ: BIIB), Halozyme Therapeutics (NASDAQ: HALO), and Ionis Pharmaceuticals (NASDAQ: IONS) stocks have all recently hit 52-week highs. What's driving these drug stocks -- and are they still smart picks for long-term investors?
Image source: Getty Images.
Source: Fool.com
Bristol-Myers Squibb Aktie
43,94 €
-2,27 %
Die Community zeigt leichtes Interesse an Bristol-Myers Squibb mit mehr Buy- als Sell-Einschätzungen.
Das Kursziel von 65 € für Bristol-Myers Squibb impliziert eine deutliche Steigerung um über 20% gegenüber 43.94 €.
